News | January 03, 2014

Cardiologists Continue Imaging Despite Isotope Shortage by Using Fewer Radiopharmaceuticals

ultraspect xpress.cardiac nuclear imaging spect radiation dose
January 3, 2014 — As the global medical isotope shortage continues indefinitely following the plant leak in South Africa, Berks Cardiologists Ltd., a cardiovascular imaging center in central Pennsylvania, is continuing to operate at the same procedure volume and with their lower-dose cardiac nuclear medicine imaging protocols. The facility relies on software from UltraSPECT, a provider of image reconstruction technology that reduces radiopharmaceutical dose and acquisition time for nuclear medicine (NM) exams.
 
Berks Cardiologists is a private practice in Wyomissing, Penn. with a staff that includes 14 cardiologists and performs about 100 SPECT exams a week. The practice was initially looking for software to improve their image quality and found a solution that only provides them with high-resolution images and the ability to use half the injected dose of the nuclear imaging agent Technetium-99m (Tc-99m).
 
"Wide Beam Reconstruction technology from UltraSPECT has been instrumental in our ability to maintain our high patient throughput throughout this technetium shortage,” said James Reibsane, CNMT, director of diagnostic and technical services, Berks. “With our protocol of low-dose imaging, our business operations continue, and our patients are all imaged as planned and as needed. Few cardiovascular imaging facilities across the country can say the same.”
 
Shortages of Tc-99m can have significant impact on healthcare facilities’ operations and, more significantly, on the care of their patients. Without a solution like the low dose software from UltraSPECT, implications can include:
-Inability to provide patients with the necessary nuclear medicine tests
-Delays and rescheduling of exams for patients
-The need to send high-risk patients for interventional procedures without the most necessary test results
-Loss of revenue to a practice 
 
“Since the heavy shortage in 2009, it is known that nuclear isotope shortages are guaranteed to happen and are nearly always unexpected,” said Yossi Srour, president and CEO, UltraSPECT. “Low dose protocols are needed now more than ever with the increase in these shortages combined with the ongoing implementation of low dose ASNC guidelines.”
 
UltraSPECT’s Xpress3.Cardiac solution uses the company’s exclusive WBR (wide-beam reconstruction) technology to deliver half-dose cardiac imaging with high image quality and undiminished diagnostic certainty. It minimizes the radiation dose to both the patients and the staff administering the exams.
 
For more information: www.ultraspect.com

Related Content

ASRT Supports Radiopharmaceutical Reimbursement Bill
News | Radiopharmaceuticals and Tracers | August 02, 2019
The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure...
NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility
News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical...
Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 26, 2018 | Dave Fornell
February 8, 2018 — The U.S.
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers | August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...